Combination of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial

Toshio Oghihara\textsuperscript{a}, Takao Saruta\textsuperscript{b}, Hiromi Rakugi\textsuperscript{c}, Ikuo Saito\textsuperscript{b}, Kazuaki Shimamoto\textsuperscript{d}, Hiroaki Matsuoka\textsuperscript{e}, Kazuyuki Shimada\textsuperscript{f}, Sadayoshi Ito\textsuperscript{g}, Masatsugu Horiuchi\textsuperscript{h}, Tsutomu Imaiuzumi\textsuperscript{i}, Shuichi Takishita\textsuperscript{j}, Jitsuo Higaki\textsuperscript{k}, Shigehiro Katayama\textsuperscript{l}, Genjiro Kimura\textsuperscript{m}, Satoshi Umemura\textsuperscript{m}, Nobuyuki Ura\textsuperscript{n}, Koichi Hayashi\textsuperscript{b}, Masato Odawara\textsuperscript{o}, Norio Tanahashi\textsuperscript{b}, Toshihiko Ishimitsu\textsuperscript{b}, Naoki Kashihara\textsuperscript{b}, Satoshi Morita\textsuperscript{m}, Satoshi Teramukai\textsuperscript{b}, for the COLM Investigators

Objective: The aim of the present study was to compare the cardiovascular effects of olmesartan, an angiotensin II receptor blocker, combined with a calcium channel blocker (CCB) or a diuretic, in a prospective, randomized, open-label, blinded endpoint trial.

Methods: Japanese hypertensive patients aged at least 65 to less than 85 years with SBP at least 140 mmHg and/or DBP at least 90 mmHg with antihypertensive treatment, or SBP at least 160 mmHg and/or DBP at least 100 mmHg without antihypertensive treatment were randomized to receive olmesartan with either a dihydropyridine CCB or a low-dose diuretic. If SBP and/or DBP remained at least 140 and/or at least 90 mmHg, the other antihypertensive drug was added. The primary endpoint was a composite of fatal and nonfatal cardiovascular events. The median follow-up time was 3.3 years.

Results: Blood pressure decreased similarly in both groups. The primary endpoint occurred in 116/2568 patients (4.5%) in the olmesartan plus CCB group and in 135/2573 patients (5.3%) in the olmesartan plus diuretic group [hazard ratio 0.83, 95% confidence interval (CI) 0.65–1.07, P = 0.16]. Rates of all-cause death and cardiovascular deaths were similar. Among patients aged at least 75 years, the incidence of stroke tended to be lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group (hazard ratio 0.63, 95% CI 0.38–1.02, P = 0.059, interaction P = 0.019). Fewer patients in the olmesartan plus CCB group (8.2%, 211/2568) than in the olmesartan plus diuretic group (9.8%, 253/2573; P = 0.046) experienced serious adverse events.

Conclusion: Despite no significant difference in cardiovascular events, the different safety profiles suggest that the combination of olmesartan and CCB may be preferable to that of olmesartan and diuretic.

Keywords: blood pressure, calcium channel blockers, diuretics, hypertension, olmesartan, randomized controlled trial

Abbreviations: ACCOMPLISH, Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CCB, calcium channel blocker; COLM, Combinations of OLMesartan; SAE, serious adverse event

INTRODUCTION

Hypertension is a major risk factor for cardiovascular morbidity and mortality [1]. Tight control of blood pressure (BP) is recommended for the prevention of cardiovascular diseases [2] and often requires combinations of two or more antihypertensive drugs [3]. Current clinical guidelines for the management of hypertension list several combinations of drugs [4–6]. Only a few studies, however, such as the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) [7] and Combination Therapy of Hypertension to Prevent Cardiovascular Events.
METHODS

Study design

The rationale, study design, and implementation of the COLM study are described in more detail in our previous report [14]. This multicentre prospective, randomized, open-label blinded-endpoint trial was conducted between April 2007 and September 2011 at 707 primary care and cardiology centres in Japan. Patient recruitment was completed in September 2008. After randomization, all patients were followed up for at least 3 years until the trial was terminated at the prespecified time. The trial was conducted in accordance with the Declaration of Helsinki. The protocol was reviewed and approved by institutional review boards at each participating centre.

Patients

Hypertensive patients aged at least 65 to less than 85 years with a history of cardiovascular disease or risk factors for cardiovascular disease, including diabetes mellitus or dyslipidaemia, were eligible for the study. Patients were enrolled if their clinic-measured SBP was at least 140 mmHg and/or their DBP was at least 90 mmHg during treatment with one or more antihypertensive drugs at enrolment, or if their SBP was at least 160 mmHg and/or DBP was at least 100 mmHg without antihypertensive treatment. All patients provided written informed consent.

Randomization and treatments

Patients were randomized 1:1 using a dynamic allocation method with stratification for sex, age (≥75/≤75 years), history of cardiovascular disease, BP (mild/moderate or severe hypertension according to the Japanese guideline for the management of hypertension [15]), prior use of antihypertensive agents, and centre. Randomization was conducted using a computerized system by the COLM study data centre, and the random allocation sequence was concealed until the end of the enrolment period. Patients were treated with olmesartan (5–40 mg/day) and either a long-acting dihydropyridine CCB (amlodipine (2.5 or 5 mg/day) or azelnidipine (8 or 16 mg/day)) or a low-dose diuretic (trichloromethiazide ≤1 mg, hydrochlorothiazide ≤12.5 mg, or indapamide ≤1 mg and other diuretics). Wherever possible, low doses of diuretics were preferred [16]. Medication was administered orally, once a day, usually after breakfast. The choice of which CCB and diuretic were used concomitantly with olmesartan was at the discretion of the investigator in charge of each patient [14].

Outcomes

Measurement of BP, assessment of cardiovascular events, and laboratory tests were conducted at 1, 3, and 6 months after randomization, and then every 6 months thereafter. BP was measured at least twice at intervals of 1–2 min, and the mean value of two stable measurements that differed by less than 5 mmHg was used. The primary endpoint was a composite of fatal and nonfatal cardiovascular events. Cardiovascular events included sudden death; new occurrence or recurrence of cerebral infarction, cerebral haemorrhage, subarachnoid haemorrhage, or transient ischaemic attack; new occurrence or recurrence of myocardial infarction; coronary revascularization (percutaneous intervention or coronary artery bypass grafting); hospitalization for angina pectoris or heart failure; and renal events (doubling of serum creatinine, serum creatinine ≥2.0 mg/100 ml, and end-stage renal disease).

Secondary endpoints included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke except transient ischaemic attack, all-cause deaths, composite of hard endpoints (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke except transient ischaemic attack), new-onset diabetes, incidence of specific events (sudden death, cerebrovascular events, cardiac events, and renal events), new occurrence of atrial fibrillation, adverse events, and the proportion of patients who withdrew from the allocated treatment. Adverse events, classified as drug-related or nondrug-related and serious or nonserious, were monitored throughout the study. All events contributing to the primary and secondary endpoints and all serious adverse events (SAEs) reported by the participating physicians were adjudicated by the Endpoint Committee, which was blinded to the study group.

Sample size

The rationale for the sample size is reported elsewhere [14]. Briefly, the incidence of cardiovascular events (i.e., the primary endpoint) was estimated to be 2% per year, and the relative difference in the incidence of cardiovascular events between the two groups was estimated to be 33%. Therefore, more than 2000 patients were needed for each...
Statistical methods
All analyses were conducted according to the intention-to-treat principle. Time-to-event curves for cardiovascular events were plotted using the Kaplan–Meier method. Stratified log-rank tests were conducted with sex, age, and history of cardiovascular disease as strata. Hazard ratios and 95% confidence intervals (CIs) were calculated using the stratified proportional hazards model. Exploratory analyses of prespecified subgroup analyses were conducted, and interactions between treatment group and each subgroup were investigated. Patient characteristics at baseline, BP at the end of the trial, and the frequency of adverse events between two groups were compared using the t-test (for continuous variables) and Fisher’s exact test (for categorical variables). The t-test was used to compare the change in BP, and the analysis of covariance adjusted by baseline data was conducted to compare the average change in heart rate between two groups. Two interim analyses were planned to either continue or discontinue the study on the basis of ethical and scientific considerations, with adjustment for repeated comparisons using the O’Brien–Fleming α-spending function, and the results were evaluated by the Independent Data Monitoring Committee. The prespecified significant levels for stopping criteria were 0.00001 for the first interim analysis and 0.003 for the second interim analysis. If these were met, the Data Monitoring Committee would ask the Steering Committee to either amend the study protocol or discontinue the study. For the primary endpoint, the significance level for the final analysis was set at 0.049 (two-sided) considering the two interim analyses. In other analyses, the level of significance was 0.05 (two-sided). All statistical analyses were done using SAS 9.1 (SAS Institute, Inc., Cary, North Carolina, USA).

RESULTS
Patients
Of 5658 patients assessed for eligibility, 489 patients met the exclusion criteria and 28 patients withdrew consent before enrolment. Therefore, 5141 patients were randomized. Overall, 46 patients in the olmesartan plus CCB group and 72 patients in the olmesartan plus diuretic group were lost to follow-up, leaving 2568 and 2573 patients in these groups, respectively (Fig. 1). The results of two interim analyses in October 2009 and December 2010 did not meet the prespecified early stopping criteria. The median follow-up period was 3.3 years (range 1 day to 4.3 years), and the follow-up rate was 98.0%. The baseline characteristics, including BP at randomization, are shown in Table 1. The mean age of patients was 73.6 years, and 51.6% were men. There were no significant differences in baseline characteristics between the two groups. Approximately 24% of patients had a history of cardiovascular diseases, including stroke (14.6%) and ischaemic heart disease (11.0%). Approximately 81% of patients were treated with antihypertensive agents at enrolment; the most common types were ARBs (49%) and CCBs (37%).

At 3 years, the mean number of antihypertensive drugs used, including the allocated drugs, was 2.1 in the olmesartan plus CCB group and 2.1 in the olmesartan plus diuretic group (P = 0.64). The median number of drugs was two in both groups.

![Patient disposition](https://www.hypertension.com)

**FIGURE 1** Patient disposition.
The following drugs were used in the olmesartan plus CCB group: amlopidine (44.9%) and azelnidipine (49.8%), and in the olmesartan plus diuretic group: trichlormethiazide (62.4%), indapamide (22.8%), hydrochlorothiazide (2.3%), and other thiazides (3.5%). The mean doses of olmesartan were 18.3 ± 8.1 and 18.5 ± 8.6 mg/day for patients in the olmesartan plus CCB and olmesartan plus diuretic groups, respectively.

**Blood pressure and heart rate**

BP at baseline was approximately 158/87 mmHg, and was similar in both groups (Table 1). The time-course of changes in SBP and DBP was similar in both groups (Fig. 2). At the end of the trial, the mean SBP/DBP was 132.9 ± 12.6/73.2 ± 9.8 mmHg in the olmesartan plus CCB group and 132.9 ± 13.6/73.5 ± 9.8 mmHg in the olmesartan plus diuretic group, corresponding to mean reductions in SBP/DBP of 24.4 ± 16.4/13.8 ± 12.0 and 24.9 ± 17.3/13.7 ± 12.4 mmHg (P = 0.30/0.79), respectively. There were no significant differences in mean SBP or DBP at each visit between the two groups.

Overall, 69.2% (1735/2568) of patients in the olmesartan plus CCB group and 70.5% (1759/2573) of patients in the olmesartan plus diuretic group (P = 0.30) achieved the target BP levels (SBP <140 mmHg and DBP <90 mmHg).

Heart rate was 73.1 and 72.9 bpm (P = 0.49) at baseline in the olmesartan plus CCB and olmesartan plus diuretic groups, respectively, and decreased slightly to 69.7 ± 11.2 and 70.5 ± 11.7 bpm, respectively, at 3 years. The decrease in heart rate was significantly greater in the olmesartan plus CCB group than in the olmesartan plus diuretic group (P = 0.01), with a mean difference of 0.55 bpm.

**Primary outcome**

Kaplan–Meier analysis of the time to the first primary endpoint is shown in Fig. 3. The incidence and hazard ratio of the primary endpoint are shown in Fig. 4. The primary endpoint occurred in 116/2568 patients (4.5%) in the olmesartan plus CCB group, and in 135/2573 patients (5.3%) in the olmesartan plus diuretic group (hazard ratio 0.83, 95% CI 0.65–1.07, P = 0.16). The incidence of the primary endpoint per 1000 patient-years was 14.8 in the olmesartan plus CCB group and 17.6 in the olmesartan plus diuretic group. There were no significant differences in the rates of each type of event between the two groups (Fig. 4).

**Secondary and other prespecified endpoints**

Overall, 64/2568 patients (2.5%) in the olmesartan plus CCB group (8.0/1000 patient-years) and 76/2573 patients (3.0%) in the olmesartan plus diuretic group (9.7/1000 patient-years) died during the study (hazard ratio 0.83, 95% CI 0.59–1.15, P = 0.27). The rates of all-cause death and cardiovascular death were not significantly different between the two groups. The composite of hard endpoints occurred in 72/2568 patients (2.8%) in the olmesartan plus CCB group and 17.6 in the olmesartan plus diuretic group.

---

**Table 1. Baseline characteristics of the study population according to treatment group**

| Characteristic                      | Olmesartan plus CCB (n = 2568) | Olmesartan plus diuretic (n = 2573) | P-Value |
|-------------------------------------|---------------------------------|-------------------------------------|---------|
| Sex                                 |                                 |                                     |         |
| Men                                 | 1323 (51.5)                     | 1330 (51.7)                         | 0.91    |
| Women                               | 1245 (48.5)                     | 1243 (48.3)                         |         |
| Age (years)                         | 73.6 ± 5.3                      | 73.6 ± 5.4                          | 0.74    |
| ≥75 years old                       | 1109 (43.2)                     | 1114 (43.3)                         | 0.95    |
| <75 years old                       | 1459 (56.8)                     | 1459 (56.7)                         |         |
| BMI (kg/m²)                         | 24.3 ± 3.5                      | 24.2 ± 3.4                          | 0.26    |
| eGFR (ml/min per 1.73 m²)           | 67.6 ± 19.0                     | 67.3 ± 18.3                         | 0.62    |
| SBP (mmHg)                          | 158.0 ± 12.7                    | 158.0 ± 12.5                        | 0.96    |
| DBP (mmHg)                          | 87.1 ± 10.8                     | 86.9 ± 10.8                         | 0.58    |
| Heart rate (bpm)                    | 73.1 ± 9.9                      | 72.9 ± 9.3                          | 0.49    |
| Cardiovascular history              |                                 |                                     |         |
| Stroke                              | 369 (14.4)                      | 382 (14.9)                          | 0.63    |
| Ischaemic heart disease             | 286 (11.1)                      | 277 (10.8)                          | 0.68    |
| Cardiovascular risk factors         |                                 |                                     |         |
| Dyslipidaemia                       | 1165 (45.5)                     | 1172 (45.8)                         | 0.84    |
| Diabetes mellitus                   | 684 (26.6)                      | 678 (26.4)                          | 0.82    |
| Smoking                             | 641 (25.1)                      | 648 (25.4)                          | 0.84    |
| Drinking                            | 1090 (42.8)                     | 1086 (42.5)                         | 0.88    |
| Use of antihypertensive drugs at enrolment* |                                 |                                     |         |
| ARB                                 | 1262 (49.2)                     | 1254 (48.9)                         | 0.84    |
| CCB                                 | 977 (37.8)                      | 916 (35.8)                          | 0.08    |
| β-Blockers                          | 231 (9.0)                       | 191 (7.5)                           | 0.04    |
| ACE inhibitors                      | 149 (5.8)                       | 154 (6.0)                           | 0.76    |
| Diuretics                           | 146 (5.7)                       | 168 (6.6)                           | 0.20    |
| α-Blockers                          | 71 (2.8)                        | 70 (2.7)                            | 1.00    |
| Concomitant use of other drugs      |                                 |                                     |         |
| Statin                              | 704 (27.5)                      | 719 (28.1)                          | 0.64    |
| Antiplatelet drugs                  | 555 (21.7)                      | 561 (21.9)                          | 0.83    |
| Antidiabetic drugs                  | 472 (18.4)                      | 497 (19.4)                          | 0.37    |

Data are n (%) or mean ± standard deviation. ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; eGFR: estimated glomerular filtration rate, calculated using the Japanese formula 194 × Cr –1.094 × age – 0.287 (×0.739 for women).

*Excludes 16 patients for whom data were not collected after randomization (n = 2563 in the olmesartan plus CCB group, n = 2562 in the olmesartan plus diuretic group).
group and in 88/2573 patients (3.4%) in the olmesartan plus diuretic group (hazard ratio 0.80, 95% CI 0.58–1.09, \( P = 0.16 \)). The rates of new-onset atrial fibrillation and diabetes were not significantly different between the two groups (Fig. 4).

Table 2 shows the results of prespecified subgroup analyses. The incidence rates of the primary endpoint among older patients (≥75 years old), in patients without diabetes, and in patients without dyslipidemia were lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group; however, the interactions were not statistically significant.

Among older patients (≥75 years old), the incidence of the composite of hard endpoints was also lower in the olmesartan plus CCB group (hazard ratio 0.64, 95% CI 0.42–0.97, \( P = 0.03 \)), although the interaction was not significant (\( P = 0.12 \)). In this subgroup, the incidence of stroke was also lower in the olmesartan plus CCB group (hazard ratio 0.63, 95% CI 0.38–1.02, \( P = 0.059 \)) and the interaction between treatment and age subgroup was statistically significant (\( P = 0.019 \)).

**Safety and adverse events**

A total of 77/2568 patients (3.0%) in the olmesartan plus CCB group and 131/2573 patients (5.1%) in the olmesartan plus diuretic group (\( P < 0.001 \)) were withdrawn because of SAEs. The incidence of SAEs was lower in the olmesartan plus CCB group (211/2568 patients, 8.2%) than in the olmesartan plus diuretic group (253/2573 patients, 9.8%) (\( P = 0.046 \)). The three most frequent SAEs were malignancy (olmesartan plus CCB vs. olmesartan plus diuretic: 2.5 vs. 6.0\%).

---

**FIGURE 2** Time-course of changes in blood pressure.

**FIGURE 3** Kaplan–Meier curves for the primary composite endpoint of fatal and nonfatal cardiovascular events.
3.1%; \( P = 0.17 \)), gastrointestinal disorders (1.1 vs. 1.1%; \( P = 0.79 \)), and infection (0.9 vs. 0.9%; \( P = 0.76 \)). New-onset diabetes occurred in 10 patients (0.4%) in the olmesartan plus CCB group and 15 patients (0.6%) in the olmesartan plus diuretic group (hazard ratio 0.66, 95% CI 0.29–1.47, \( P = 0.30 \)). Regarding laboratory events, the incidence of hyperuricaemia was greater in the olmesartan plus diuretic group than in the olmesartan plus CCB group (6.5 vs. 2.6%, \( P < 0.001 \)).

**DISCUSSION**

Over a median follow-up period of 3.3 years, there were no differences in the cardiovascular risk reduction conferred

---

**TABLE 2. Results of prespecified subgroup analyses for the primary endpoint**

| Subgroup                          | Olmesartan plus CCB (\( n = 2568 \)) | Olmesartan plus diuretic (\( n = 2573 \)) | Hazard ratio (95% CI) | \( P \)-Value | \( P \)-Value (interaction) |
|-----------------------------------|-------------------------------------|------------------------------------------|-----------------------|---------------|---------------------------|
| *Sex*                             |                                     |                                          |                       |               |                           |
| Men                               | 63/1323 (4.8)                       | 76/1330 (5.7)                           | 0.82 (0.58–1.14)      | 0.24          | 0.81                      |
| Women                             | 53/1345 (4.3)                       | 59/1243 (4.7)                           | 0.87 (0.60–1.26)      | 0.46          |                           |
| *Age*                             |                                     |                                          |                       |               |                           |
| <75 years old                     | 58/1459 (4.0)                       | 55/1459 (3.8)                           | 1.03 (0.71–1.49)      | 0.85          | 0.14                      |
| \( \geq 75 \) years old           | 58/1109 (5.2)                       | 80/1114 (7.2)                           | 0.70 (0.50–0.99)      | 0.04          |                           |
| *BMI* (kg/m\( ^2 \))             |                                     |                                          |                       |               |                           |
| <25                               | 76/1525 (5.0)                       | 93/1527 (6.1)                           | 0.81 (0.59–1.09)      | 0.17          | 0.74                      |
| \( \geq 25 \)                      | 40/1022 (3.9)                       | 41/1018 (4.0)                           | 0.94 (0.60–1.45)      | 0.78          |                           |
| *eGFR* (ml/min per 1.73 m\( ^2 \))|                                     |                                          |                       |               |                           |
| <60                                | 43/622 (6.9)                        | 52/642 (8.1)                            | 0.82 (0.55–1.24)      | 0.35          | 0.94                      |
| \( \geq 60 \)                      | 47/1230 (3.8)                       | 55/1224 (4.5)                           | 0.83 (0.56–1.23)      | 0.37          |                           |
| *Diabetes mellitus*               |                                     |                                          |                       |               |                           |
| Yes                                | 48/684 (7.0)                        | 42/678 (6.2)                            | 1.12 (0.74–1.69)      | 0.58          | 0.06                      |
| No                                 | 68/1884 (3.6)                       | 93/1895 (4.9)                           | 0.71 (0.52–0.97)      | 0.03          |                           |
| *Dyslipidemia*                    |                                     |                                          |                       |               |                           |
| Yes                                | 68/1165 (5.8)                       | 66/1172 (5.6)                           | 1.01 (0.72–1.41)      | 0.94          | 0.08                      |
| No                                 | 48/1398 (3.4)                       | 69/1390 (5.0)                           | 0.68 (0.47–0.98)      | 0.03          |                           |
| *History of cardiovascular disease*|                                     |                                          |                       |               |                           |
| Yes                                | 55/610 (9.0)                        | 59/615 (9.6)                            | 0.90 (0.62–1.30)      | 0.58          | 0.61                      |
| No                                 | 61/1958 (3.1)                       | 76/1958 (3.9)                           | 0.78 (0.56–1.10)      | 0.16          |                           |

Data are \( n \) of patients reaching the primary endpoint/total \( n \) (%). CCB, calcium channel blocker; CI, confidence interval; eGFR, estimated glomerular filtration rate.
using olmesartan, an ARB, in combination with either a CCB or a diuretic. The incidence of SAEs, however, was significantly lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group. Patients in the present study were well matched in terms of age, obesity, history of cardiovascular disease, cardiovascular risk factors, and antihypertensive medications. BP at baseline and 3 years were similar in both groups, with comparable reductions in BP in both groups.

Several studies have examined the effects of combinations of antihypertensive drugs with different mechanisms of action. For example, the ACCOMPLISH trial showed that the combination of an ACE inhibitor and a CCB was superior to that of an ACE inhibitor and a diuretic for preventing cardiovascular events [7], and the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial showed that the combination of a CCB and a diuretic was superior to that of a CCB and a β-blocker [8]. Among studies examining the efficacy of add-on antihypertensive drugs, the Losartan Intervention For Endpoint reduction in hypertension study showed that an ARB-based regimen with an add-on diuretic was superior to a β-blocker-based regimen with an add-on diuretic for preventing cardiovascular events [17], whereas the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm showed that a CCB-based regimen with an add-on ACE inhibitor was superior to a β-blocker-based regimen with an add-on diuretic [18]. The results of these two studies suggested that the combination of an ARB and a diuretic or a CCB and an ACE inhibitor had some advantages over that of a β-blocker and a diuretic for treating hypertension. In the present study, we compared two widely used combinations of hypertensive drugs: an ARB and a CCB, an ARB and a diuretic.

The primary endpoint, a composite of cardiovascular morbidity and mortality, and its individual components were not significantly different between the two groups in our study, indicating that both combinations conferred similar reductions in cardiovascular risk in elderly hypertensive patients, consistent with earlier studies showing that BP lowering is essential to reduce cardiovascular morbidity and mortality in hypertensive patients [19–21]. Although the present results do not support the conclusion of the ACCOMPLISH trial [7] that the combination of a renin–angiotensin system (RAS) inhibitor and a CCB is superior to that of a RAS inhibitor and diuretic, we could not consider a smaller relative risk reduction such as 19.6% in the ACCOMPLISH trial, because the present study was specifically powered to detect a relative risk reduction of 35% between the two groups [14]. Nevertheless, the reason why the present results do not support those of the ACCOMPLISH trial may be differences in the races of study patients and the use of an ACE inhibitor vs. an ARB. The higher salt sensitivity in the older Japanese patients (mean age: 73.6 years) in our study than that in the slightly younger predominantly white (83.5%) (mean age: 68.4 years) patients in the ACCOMPLISH trial may have caused greater efficacy of the combination of the RAS inhibitor and diuretic in our study relative to theirs. Another important issue is that stroke was the most common component of the primary endpoint (51.4%) in our study, whereas myocardial infarction (23.1%) and coronary revascularization (58.5%) were more common in the ACCOMPLISH trial. The different pattern of endpoints between the two trials may be related to differences in ethnicity and the severity of cardiac risk at enrolment. It is well known that the incidence of stroke is more strongly associated with BP than is myocardial infarction. Indeed, the two groups in our study achieved similar SBP with a similar incidence of stroke. Although the incidence of the primary endpoint was not significantly different between the two groups, the prespecified subgroup analyses showed that the incidence of stroke among patients aged at least 75 years tended to be lower in the olmesartan plus CCB group (P = 0.059), with a statistically significant interaction (P = 0.019), which should be confirmed in future studies.

There were more SAEs and also SAEs that required treatment discontinuation in the olmesartan plus diuretic group than in the olmesartan plus CCB group. Furthermore, hyperuricaemia was more common in the olmesartan plus diuretic group, even though low doses of diuretics were used. On the basis of these tolerability issues, we suggest that the combination of an ARB and CCB may be preferable to that of an ARB and diuretic for elderly hypertensive patients.

Guidelines for the treatment of hypertension currently recommend target SBP/DBP less than 140/less than 90 mmHg for general hypertensive patients [4–6]. To achieve such targets, it is often necessary to use multiple antihypertensive drugs of different classes. Consequently, numerous clinical trials have used two or more antihypertensive drugs [21,22]. In recent years, various combination antihypertensive drugs have been launched, and fixed combinations of two antihypertensive drugs are now widely used in clinical practice. In the United States, the combination of a RAS inhibitor and a diuretic or a CCB is the preferred one, whereas that of a CCB and β-blocker or a diuretic is an acceptable one [23]. These recommendations, however, are not fully supported by clinical evidence. Therefore, further studies are necessary to provide adequate clinical evidence to either support or change the current clinical recommendations. Additionally, it will also be necessary to determine the safety profiles and cardiovascular risk reduction associated with the use of other ARBs in combination with a β-blocker, CCB, or diuretic.

Some limitations warrant mention. First, we used the method of prospective, randomized, open-label blinded-endpoint trial, which may lead to some investigator bias. Because BP control was similar in both groups, however, it is unlikely that some investigator bias affected the main outcomes of this study. Regarding statistical power, the incidence of the primary endpoint was close to the expected incidence. Because the sample size was designed to detect a relative difference of 33%, however, more patients were necessary to detect the smaller than expected difference in the incidence of the primary endpoint. Another limitation is that we only enrolled Japanese elderly hypertensive patients, so the results may not be generalizable to other populations.

In conclusion, antihypertensive drugs are widely prescribed to reduce the risk of serious cardiovascular events in patients deemed to be at high risk of such events. The
current clinical guidelines for the management of hypertension advocate the use of multiple antihypertensive drugs in combination to help reach BP targets. Although there is abundant evidence supporting the use of combination therapy, very few studies have compared different combinations of drugs. We found no marked differences in the cardiovascular risk reduction by using olmesartan together with either a CCB or a diuretic. When considering the safety aspects, however, a regimen consisting of olmesartan and a CCB may be preferable to olmesartan in combination with a diuretic. Well designed studies are needed to compare the cardiovascular risk reduction profiles and safety profiles of combination regimens based on an ARB, ACE inhibitor, or CCB.

ACKNOWLEDGEMENTS

We thank the collaborators and members of the COLM Study Group.

The present work was supported by a grant from Japan Heart Foundation. The Japan Heart Foundation had no input into the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Conflicts of interest

T.O., T.S., H.R., I.S., K.Shimamoto, H.M., K.Shimada, S.I., M.H., T.I., S.T., J.H., S.K., G.K., N.U., K.H., M.O., N.T., T.I., S.U., N.K., and S.T. have received travel expenses, payment for speaking at meetings, or funding for research from one or more pharmaceutical companies that market antihypertensive drugs, including Daiichi Sankyo Co. Ltd. S.M. has no conflicts of interest to disclose.

Appendix

COLM study committees

Executive and Writing Committee: T. Saruta (Co-Chair, Keio University), T. Oghira (Co-Chair, Morinomiya University of Medical Sciences), H. Rakugi (Secretary, Osaka University Graduate School of Medicine), and I. Saito (Keio University).

Steering Committee: K. Shimamoto (Sapporo Medical University), S. Ito (Tohoku University Graduate School of Medicine), H. Matsuoka (Dokkyo Medical University), K. Shimada (Shin-Oyama City Hospital), M. Horiiuchi (Ehime University Graduate School of Medicine), T. Imaizumi (Kurume University School of Medicine), and S. Takishita (University of the Ryukyus School of Medicine).

Protocol Committee: K. Shimada (Shin-Oyama City Hospital), N. Ura (Sapporo Nishimaruayama Hospital), K. Hayashi (Keio University), and H. Rakugi (Osaka University Graduate School of Medicine).

Endpoint Committee: J. Higaki (Ehime University Graduate School of Medicine), M. Odawara (Tokyo Medical University), N. Tanahashi (Saitama Medical University), and G. Kimura (Asahi Rousai Hospital).

Independent Data Monitoring Committee: S. Katayama (Saitama Medical University), S. Umemura (Yokohama City University Graduate School of Medicine), T. Ishimitsu (Dokkyo Medical University), N. Kashihara (Kawasaki Medical School), and S. Morita (Yokohama City University Graduate School of Medicine).

Statistical Committee: I. Saito (Keio University) and S. Teramukai (Kanazawa University Hospital).

Ethics committee: Y. Uetsuka (Tokyo Women’s Medical University), M. Fujikawa (Edogawa City Office), R. Nago (Marunouchi Minami Law Office), and M. Ito (Chibaiken Certified Public Tax Accountants’ Association).

COLM study investigators

T. Anno, S. Aoyama, N. Arima, Y. Bando, Y. Dohi, H. Fujioka, M. Fukuda, S. Fukuda, M. Fukuta, Y. Futamura, Y. Hirakawa, K. Imaeda, H. Imai, A. Imamura, M. Ito, O. Ito, T. Ito, T. Iwa, J. Izumi, Y. Kaga, K. Kanematsu, Y. Kato, Y. Kawata, T. Kitamura, K. Kobayashi, M. Koyasu, S. Kuwabara, M. Kuzuya, M. Maekawa, M. Miura, F. Mitsuuchi, T. Murohara, N. Naita, N. Negi, Y. Numaguchi, T. Ohya, S. Okayama, K. Okuma, N. Ozaki, N. Ozeki, K. Sato, T. Sawada, Y. Seino, M. Suezawa, T. Suzuki, Y. Suzuki, N. Takahashi, R. Takahashi, N. Tanaka, Y. Wakida, H. Watanuki, M. Watarai, K. Yamada, Y. Yamashita, Y. Yoshikane (Aichi), M. Goto, Y. Ishida, H. Kimura, K. Takahashi, N. Yashima (Akita), Y. Abe, S. Fujiiwara, H. Higashino, M. Kaizuka, O. Minami, Y. Ogii, T. Osanai, T. Sasaki, A. Sato, K. Sugimoto, H. Takahashi, K. Tanabe (Aomori), D. Azuma, C. Ikuki, H. Inoya, T. Iyo, M. Kusaka, M. Ogawa, Y. Okubo, H. Rinno, M. Sano, T. Shishikura, H. Takahara, M. Takano, T. Takemura, S. Yamamoto, Y. Yonemitsu (Chiba), M. Hasui, T. Honda, M. Igase, S. Kimoto, K. Kohno, S. Kondo, T. Oonishi, H. Saeki, T. Sunayama, H. Takahashi, C. Wakisaka, H. Watanabe, K. Watanabe (Ehime), Y. Iwashiro (Fukuin), Alan H.C. Lau, S. Ando, H. Eguchi, M. Fujino, J. Fujiki, T. Gondo, S. Hatakeyama, K. Hirano, Y. Hirooka, H. Ikeda, T. Inou, T. Jinnouchi, T. Kadokami, H. Kai, H. Kameo, M. Kaneyuki, A. Kato, H. Kishikawa, H. Koizawa, K. Kusaba, S. Maeda, S. Maki, M. Matsumoto, T. Matsumoto, J. Matsumoto, S. Matsuo, H. Meno, S. Miki, J. Miyagi, T. Miyauchi, S. Mori, M. Nagashima, S. Nagata, R. Nakamura, T. Nakamura, H. Niiyama, K. Noda, M. Nohara, Y. Ohta, I. Onitsuka, T. Otonari, S. Ouma, T. Sakisaka, K. Saku, K. Sasaki, S. Sasaki, Y. Sawayaama, M. Shihara, K. Shiotani, K. Shirakawa, Y. Tachikawa, S. Takemura, T. Takeuchi, M. Tanabe, M. Tanaka, T. Tashiro, M. Tatsukawa, T. Tsuchihashi, T. Tsuchi, T. Tsuiki, T. Tsutsui, Y. Uehara, H. Umez, T. Yamada, J. Yamagata, S. Fukuoka, T. Ajihara, K. Hagiwara, S. Imamura, M. Inoue, I. Konno, K. Konto, Y. Kubota, H. Kuma, T. Kuwana, T. Mitsuhashi, Y. Miyazaki, J. Nagashima, M. Nambu, T. Nishimaki, S. Sato, Y. Taneda, T. Tezuka, T. Yabuki (Fukushima), F. Ando, Y. Fuwa, S. Umeda (Gifu), O. Araki, Y. Furushima, Y. Hattori, H. Hirabayashi, M. Horigome, J. Hoshino, C. Iguchi, H. Inamura, H. Kuwauchi, S. Kogure, H. Kubo, F. Nagamata, T. Nagao, T. Nagao, S. Nagata, H. Nakashima, Y. Shimizu, H. Shoda, M. Tachibana, K. Yabe (Gunma), R. Kuwashima, R. Mouri, T. Murakami, H. Muraoka, S. Nomura, F. Okuno, N. Sasaki, R. Sasaki, T. Sato, M. Shirakata, H. Sugin, H. Takahashi, H. Takemoto (Hirosima), J. Ashihara, T. Betsuyaku, T. Fujita, T. Haga, M. Hayashi, Y. Hayashi, K. Hirasawa, Y. Ishii, R. Ishimoto, T. Komakine, M. Kyuma, I. Maeda, H. Matsuda, T. Matsuki, T. Matsumoto, T. Mitto, M. Mizutani, H. Morimoto, S. Natori, T. Nishimiya, M. Nishimura, H. Oimatsu, N. Oosawa, S.
References

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571–1576.
2. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055–1076.
3. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14:295–301.
4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA 2014; 311:507–520.
5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013ESH/ESCguidelinesforthemanagementofarterialhypertension:theTaskForcedomannagementofarterialhypertensionoftheEuropeanSocietyofHypertension(ESH)andoftheEuropeanSocietyofCardiology(ESC). J Hypertens 2013; 31:1281–1357.
6. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32:5–107.
7. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlopidine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428.
8. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29:1649–1659.
9. Imai E, Chan JC, Ito S, Kobayashi F, Haneda M, Makino H. ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54:2978–2986.
10. Haller H, Ito S, Izso JJ, Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907–917.
11. Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, Olmesartan and Calcium Antagonists Randomized (OSCAR) Study Group. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 2012; 125:981–990.
12. Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Shirayama M, Hiramatsu K, Kobayashi F. OMEGA Study Group. Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study. Hypertens Res 2012; 35:1136–1144.
13. Matsu Y, Eguchi K, O’Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716–725.
14. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, et al., COLM Study Investigators. Rationale, study design and implementation of the COLM study: the Combination of Olmesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32:163–167.
15. Japanese Society of Hypertension. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29:51–5105.
16. Murai K, Obara T, Ohkubo T, Metoki H, Oikawa T, Inoue R, et al., J-Home Study Group. Current usage of diuretics among hypertensive patients in Japan: the Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 2006; 29:857–896.
17. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beever G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertensive study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1005.
18. Wedel H, Beever DG, Caulfield M, Collins R, Kjeldsen SE, Kristinnson A, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlopidine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895–906.
19. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527–1535.
20. Blood Pressure Lowering Treatment Trials’ Collaboration Turnball F, Neal B, Pleffer M, Kostis J, Alpert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system. J Hypertens 2007; 25:951–958.
21. Blood Pressure Lowering Treatment Trials’ Collaboration Turnball F, Neal B, Nimoniyi T, Alpert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008; 336:1121–1125.
22. Copley JB, Rosario R. Hypertension: a review and rationale of treatment. Dis Mon 2005; 51:548–614.
23. Gradman AH, Basile JN, Carter BL, Bakris GL. American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:42–50.

Reviewer’s Summary Evaluation

Reviewer 1

For decades the investigation of the treatment of arterial hypertension in randomized controlled trials has consisted of the theoretical comparison of two monotherapies to which later on and if required one, two, or more drugs were added in a nonrandomized way. In many of those studies different combination therapies were used during the trial coming to complicate the final conclusions of those trials. The present study compares two combinations using olmesartan as a common drug that combines either with a diuretic or with a calcium channel blocker. This type of study design initiated with the ACCOMPLISH study is, in my opinion, the most adequate to test the capacity of what the great majority of patients with arterial hypertension require for the control of BP, combination therapy.